Milestone Pharmaceuticals Inc.
NASDAQ:MISTBiotechnology
-$0.00 today
- Market cap
- $57.32M
- Beta
- 0.96
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$0.52
Volume 2.23M
Average 1.99M
MIST Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Milestone Pharmaceuticals Inc.NASDAQ: MIST
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $4.82M fell 69.0% year over year, behind the -4.4% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 63.7% from the prior quarter. Over 3 fiscal years it compounded at -11.4% a year.
Context
- Selling, general & admin amounted to 1117.3% of revenue in FY2025.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $48.41M (+180.2%) for the fiscal year ending Dec 2026, a step up from the -37.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $4.82M-63.7% QoQ
- Last fiscal yearDec 2025
- $17.27M-37.7% YoY
- LTMMar 2026
- $34.83M-4.4% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 17.27M USD
- Year-over-year change
- -37.7%
- 4-year CAGR
- -2.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.27M | -37.7% |
| FY2024 | 2024-12-31 | 27.75M | -10.6% |
| FY2023 | 2023-12-31 | 31.05M | +25.1% |
| FY2022 | 2022-12-31 | 24.81M | +27.9% |
| FY2021 | 2021-12-31 | 19.4M | — |
Selling, General & Admin vs competitors
How MIST compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -4.4% is the 5th highest of 8, against a peer median of -3.8%.
- Selling, general & admin amounts to 1952.5% of revenue for MIST, versus a peer median of 599.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $34.83M USD | -4.4% | -11.4% | 1952.5% | |
| LTM Mar 2026 | $22.56M USD | +1.9% | +16.6% | — | |
| LTM Mar 2026 | $19.01M USD | -17.8% | -9.7% | 599.8% | |
| LTM Mar 2026 | CHF 16.11M CHF | -3.8% | -12.0% | — | |
| LTM Mar 2026 | $15.52M USD | -5.5% | -6.6% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $13.7M USD | +20.3% | +31.5% | — |
| LTM Mar 2026 | $13.02M USD | +27.1% | +2.6% | 2479.6% | |
| FY2025 | €11M EUR | -7.8% | -8.7% | 394.7% | |
| Peer median (excluding MIST) | — | -3.8% | -6.6% | 599.8% | |
Competitors are the stored peer set for MIST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 15M | 5M | 1M | 0 | 1.55M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 114K |
| Gross Profit | 15M | 5M | 1M | 0 | 1.43M |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | 92.6% |
| Research & Development | 38.67M | 39.83M | 31.05M | 14.36M | 18.11M |
| Selling, General & Admin | 19.4M | 24.81M | 31.05M | 27.75M | 17.27M |
| Operating Expenses | 58.07M | 64.64M | 62.1M | 42.1M | 63.92M |
| Depreciation & Amortization | 93K | 89K | 92K | 105K | 114K |
| EBITDA | (42.76M) | (58.3M) | (57.04M) | (37.83M) | (59.45M) |
| EBITDA Margin | -285.1% | -1166.0% | -5703.9% | — | -3845.5% |
| Operating Income | (43.07M) | (59.64M) | (61.1M) | (42.1M) | (62.49M) |
| Operating Margin | -287.2% | -1192.8% | -6109.8% | — | -4041.7% |
| Interest Income | 220K | 1.25M | 3.97M | 4.16M | 2.92M |
| Interest Expense | 0 | 0 | 2.55M | (3.58M) | 3.84M |
| Other Income / Expenses | 220K | 1.25M | 1.41M | 583K | (918K) |
| Income Before Tax | (42.85M) | (58.39M) | (59.69M) | (41.52M) | (63.4M) |
| Pre-Tax Margin | -285.7% | -1167.8% | -5968.5% | — | -4101.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | (345K) |
| Net Income | (42.85M) | (58.39M) | (59.69M) | (41.52M) | (63.06M) |
| Net Margin | -285.7% | -1167.8% | -5968.5% | — | -4078.8% |
| EPS (Basic) | (1.02) | (1.35) | (1.39) | (0.67) | (0.75) |
| EPS (Diluted) | (1.02) | (1.35) | (1.39) | (0.67) | (0.75) |
| Weighted Avg Shares | 41.83M | 42.45M | 42.96M | 62.21M | 83.88M |
| Weighted Avg Shares (Diluted) | 41.83M | 42.45M | 42.96M | 62.21M | 83.88M |
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
Intrinsic Alpha fair value
Locked
Current Price
$0.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.